Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain (DULOPLASM)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02846701|
Recruitment Status : Unknown
Verified July 2016 by University Hospital, Strasbourg, France.
Recruitment status was: Not yet recruiting
First Posted : July 27, 2016
Last Update Posted : July 27, 2016
The primary purpose of this protocol is to evaluate the lowest plasma concentration (ie before the daily taking dose of duloxetine) in patients relieved of at least 30% of their neuropathic pain with duloxetine treatment.
The secondary purpose of this protocol is to determine plasmatic concentration peak (ie 6 hours after taking duloxetine) in patients relieved of at least 30% of their neuropathic pain with duloxetine treatment.
Others secondary purposes are to evaluate the intensity of neuropathic pain, to assess the degree of pain relief and to evaluate the sensation of the global improvement experienced by the patient.
|Condition or disease||Intervention/treatment||Phase|
|Neuropathic Pain||Drug: duloxetine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||DULOPLASM Study: Pilot Study on Mechanisms of Analgesic Action of Duloxetine: Effective Dosage of Duloxetine at the Peak and at the Lowest Plasma Concentrations|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||August 2017|
|patient treated by duloxetine||
The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
- Measurement of the lowest plasma concentration of duloxetine in pmol/mL. [ Time Frame: The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample taken at the inclusion visit (V0), before the daily morning dose of duloxetine. ]
- Measurement of the plasma concentration peak of duloxetine in pmol/mL. [ Time Frame: The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample taken during the V1 visit (28 days after V0, 6 hours after the daily morning dose of duloxetine). ]
- Intensity of his pain assessed by Numeric Rating Scale (NRS) in 11 points. [ Time Frame: at inclusion visit V0 and at V1 visit (28 days after the inclusion visit V0). ]The patient will daily report the intensity of his pain on a Numeric Rating Scale (NRS) in 11 points. The mean intensity of pain is measured at V0 and V1 visits.
- Sensation of improvement [ Time Frame: at inclusion (V0 visit) ]The sensation of improvement experienced by the patient is assessed at V0 visit on a patient's global impression of change (PGIC) in 7 points scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02846701
|Contact: Eric SALVAT, MD||184.108.40.206.13 ext firstname.lastname@example.org|